WHO reports cases is of acute hepatitis with markedly elevated liver enzymes, often with jaundice etc in children aged up to 10 years
GENEVA, Apr 16 (The CONNECT) - The World Health Organisation (WHO) is keeping a close watch on the recent “unexpected significant increase” in cases of severe acute hepatitis of unknown aetiology in young children in the United Kingdom.
Although the potential role of adenovirus and/or SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) in the pathogenesis of these cases is one hypothesis, other infectious and non-infectious factors need to be fully investigated to properly assess and manage the risk, the WHO said.
As there is an on-going increasing trend in cases in the United Kingdom over the past month together with more extensive case searching, it is very likely that more cases will be detected before the aetiology has been found - either biological, chemical or other agent(s) - and corresponding appropriate control and prevention measures have been taken.
The WHO is closely monitoring the situation with other Member States and the United Kingdom and partners for cases with similar profiles.
On 5 April 2022, the International Health Regulations (IHR) National Focal Point (NFP) for the United Kingdom notified WHO of 10 cases of severe acute hepatitis of unknown aetiology in previously healthy young children (age range: 11 months to five-year-old) across central Scotland. Of these 10 cases, nine had onset of symptoms in March 2022 while one case had an onset of symptoms in January 2022. Symptoms included jaundice, diarrhoea, vomiting and abdominal pain. All 10 cases were detected when hospitalised.
As of 8 April 2022, further investigations across the United Kingdom have identified a total of 74 cases (including the 10 cases) fulfilling the case definition1. The clinical syndrome in identified cases is of acute hepatitis with markedly elevated liver enzymes, often with jaundice, sometimes preceded by gastrointestinal symptoms, in children principally up to 10 years old. Some cases have required transfer to specialist children’s liver units and six children have undergone liver transplantation. As of 11 April, no death has been reported among these cases and one epidemiologically linked case has been detected.
Laboratory testing has excluded hepatitis type A, B, C, and E viruses (and D where applicable) in these cases while SARS-CoV-2 and/or adenovirus have been detected in several cases. The United Kingdom has recently observed an increase in adenovirus activity, which is co-circulating with SARS-CoV-2, though the role of these viruses in the pathogenesis (mechanism by which disease develops) is not yet clear. No other epidemiological risk factors have been identified to date, including recent international travel. Overall, the aetiology of the current hepatitis cases is still considered unknown and remains under active investigation. Laboratory testing for additional infections, chemicals and toxins is underway for the identified cases.
Following the notification from the UK, less than five cases (confirmed or possible) have been reported in Ireland, further investigations into these are ongoing. Additionally, three confirmed cases of acute hepatitis of unknown aetiology have been reported in children (age range 22-month-old to 13-year-old) in Spain. The national authorities are currently investigating these cases.
Clinical and public health response has been implemented across the United Kingdom to coordinate case finding with investigation into the cause of illness in these cases.
Further investigations by the national authorities are ongoing to include more detailed exposure history, toxicology testing, and additional virological/microbiological tests. Guidance has been issued to experts to support a thorough investigation of suspected cases.
Further investigations and a clinical and public health response to the cases reported are also being undertaken in Ireland and Spain.
